SCHEMBL2898704

SCHEMBL2898704

CC1(C)CC(n2c(=O)c(O)c3n(c2=O)CCN(Cc2ccc(F)cc2)C3=O)CCO1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 1/20 0.41
JAK1 P23458 1/20 0.41
JAK3 P52333 1/20 0.41
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
TP53 P04637 4/20 0.38
LMNA P02545 2/20 0.37
KCNH2 Q12809 1/20 0.36
GRM2 Q14416 1/20 0.36
CYP2D6 P10635 1/20 0.36
HRH3 Q9Y5N1 1/20 0.36
ALDH1A1 P00352 2/20 0.35
KDM4E B2RXH2 1/20 0.35
HPGD P15428 1/20 0.35
ALOX15 P16050 1/20 0.35
HSD17B10 Q99714 1/20 0.35
TSHR P16473 1/20 0.34
CRHBP P24387 1/20 0.34
CRHR2 Q13324 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2900613 0.86 KCNH2 (0.39) MEN1KMT2ASMN1; SMN2TP53LMNA
SCHEMBL2898803 0.85 KCNH2 (0.38) SMN1; SMN2TP53LMNAKCNH2GRM2
SCHEMBL2899147 0.84 KCNH2 (0.38) MEN1KMT2ASMN1; SMN2TP53LMNA
SCHEMBL2898715 0.83 NPSR1 (0.48) SMN1; SMN2TP53LMNAKCNH2GRM2
SCHEMBL2898773 0.83 TSHR (0.46) SMN1; SMN2TP53LMNAKCNH2GRM2
SCHEMBL2898693 0.82 NPSR1 (0.47) SMN1; SMN2TP53LMNAKCNH2GRM2
SCHEMBL2900488 0.82 NPSR1 (0.47) SMN1; SMN2TP53LMNAKCNH2GRM2
SCHEMBL2898763 0.82 TP53 (0.48) MEN1KMT2ASMN1; SMN2TP53LMNA
SCHEMBL2899910 0.82 TSHR (0.41) SMN1; SMN2TP53LMNAKCNH2GRM2
SCHEMBL2895568 0.81 TSHR (0.42) SMN1; SMN2TP53LMNAKCNH2GRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7820680-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2010-10-26 US claimed
EP-1725102-A4 HIV INTEGRASE INHIBITORS MERCK & CO INC (US) 2009-04-29 EP claimed
US-20080009490-A1 Hiv Integrase Inhibitors MERCK SHARP & DOHME CORP. 2008-01-10 US claimed
EP-1725102-A1 HIV INTEGRASE INHIBITORS Merck & Co., Inc. (US) 2006-11-29 EP claimed
WO-2005092099-A1 HIV INTEGRASE INHIBITORS MERCK & CO., INC. (US) 2005-10-06 WO claimed
US-7820680-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2010-10-26 US disclosed
US-7820680-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2010-10-26 US disclosed
US-20080009490-A1 Hiv Integrase Inhibitors MERCK SHARP & DOHME CORP. 2008-01-10 US disclosed
US-20080009490-A1 Hiv Integrase Inhibitors MERCK SHARP & DOHME CORP. 2008-01-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080009490-A1 Hiv Integrase Inhibitors TYMS, UNG, TYMP JAK2 2271/4885JAK1 1396/4885JAK3 1592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.